Hinge Bio
PrivateLast Round
Series A
Jan 15, 2025
Est. Valuation
$46M
Total Funding Raised
$30M
Company Overview
Hinge Bio operates in Healthcare & Life Sciences and is based in Burlingame, California. Its latest recorded funding round was a Series A round in January 2025.
Hinge Bio is a biotechnology company that develops multispecific antibody therapeutics for autoimmune diseases, inflammatory diseases, and cancer using its proprietary GEM-DIMER™ platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hinge Bio Comparables
Compare Hinge Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| UCB | 79% | |
| Dren Bio | 78% | |
| Cullinan Oncology | 77% |
For institutional investors. Book with your work email.
Hinge Bio Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Hinge Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Thornapple River Capital | Series A |
| Ridgeback Capital | Series A |
| InVivium Capital | Series A |
| Point72 | Series A |
| Lightswitch Capital | Series A |
| Point72 Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 20, 2026
Monthly visitors increased 70% MoM.
- Oct 13, 2025
Regulatory milestone achieved for Lupus therapy, enabling clinical trials.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 9, 2026
Hinge Bio presents early clinical and additional preclinical HB2198 data at ACR Convergence 2026 in Orlando, Florida, on Nov 9th '26.
- attends_eventNov 9, 2026
Hinge Bio provides clinical and additional preclinical data on HB2198 at American College of Rheumatology (ACR) Convergence 2026 in Florida, held Nov 6th-11th '26.
- adopts_technologySep 16, 2026
Hinge Bio uses Medrio’s EDC, ePRO, and RTSM modules as a single platform for Phase I trial operations, citing accelerated timelines, predictable costs, and reduced site burden.
For institutional investors. Book with your work email.
Hinge Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Hinge Bio's valuation, stock price, and market status.
Is Hinge Bio a public or private company?
Hinge Bio is a private company.
What is the current stock price of Hinge Bio?
Hinge Bio is a private company, so its shares have no public market price. Caplight tracks Hinge Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Hinge Bio worth (valuation)?
Hinge Bio's valuation is estimated at $46.0M based on funding round data.
Can I buy Hinge Bio stock?
Hinge Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Hinge Bio's last funding round?
Hinge Bio's most recent funding round was Series A on January 15, 2025.
Who are the main investors in Hinge Bio?
Key investors in Hinge Bio include Point72, Point72 Ventures.
Will Hinge Bio IPO soon?
No public IPO plans have been announced for Hinge Bio.
How can I track Hinge Bio secondary market activity?
Caplight tracks bids, offers, and trades in Hinge Bio's shares on secondary markets.